Papilloma virus vaccine

Abstract

A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections caused by papilloma virus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papilloma virus L1 protein or a combination of papilloma virus L1 protein and papilloma virus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs.

1 . An isolated HPV-16 L1 protein encoded by a polynucleotide in which the first methionine codon of said polynucleotide corresponds to the second ATG codon of an HPV-16 L1 gene.  
     
     
         2 . An immunogenic composition that comprises the HPV-16 L1 protein of  claim 1 .  
     
     
         3 . The immunogenic composition of  claim 2 , further comprising an adjuvant.  
     
     
         4 . A virus-like particle that comprises the HPV-16 L1 protein of  claim 1 .  
     
     
         5 . An immunogenic composition that comprises the virus-like particle of  claim 4 .  
     
     
         6 . The immunogenic composition of  claim 5 , further comprising an adjuvant.  
     
     
         7 . An isolated HPV-16 L1 protein encoded by a 1518 base pair polynucleotide in which the first methionine codon of said polynucleotide corresponds to the second ATG codon of an HPV-16 L1 gene.  
     
     
         8 . An immunogenic composition that comprises the HPV-16 L1 protein of  claim 7 .  
     
     
         9 . The immunogenic composition of  claim 8 , further comprising an adjuvant.  
     
     
         10 . A virus-like particle that comprises the HPV-16 L1 protein of  claim 7 .  
     
     
         11 . An immunogenic composition that comprises the virus-like particle of  claim 10 .  
     
     
         12 . The immunogenic composition of  claim 11 , further comprising an adjuvant.  
     
     
         13 . An isolated HPV-16 L1 protein encoded by a polynucleotide consisting essentially of a polynucleotide segment that begins at nucleotide 5637 of the HPV16 genome.  
     
     
         14 . An immunogenic composition that comprises the HPV-16 L1 protein of  claim 13 .  
     
     
         15 . The immunogenic composition of  claim 14 , further comprising an adjuvant.  
     
     
         16 . A virus-like particle that comprises the HPV-16 L1 protein of  claim 13 .  
     
     
         17 . An immunogenic composition that comprises the virus-like particle of  claim 16 .  
     
     
         18 . The immunogenic composition of  claim 17 , further comprising an adjuvant.  
     
     
         19 . An isolated HPV-16 L1 protein that has the N-terminal amino acid sequence MSLWLPSEA (last 9 amino acids of SEQ ID NO: 3) or SLWLPSEA (last 8 amino acids of SEQ ID NO: 3).  
     
     
         20 . An immunogenic composition that comprises the HPV-16 L1 protein of  claim 19 .  
     
     
         21 . The immunogenic composition of  claim 20 , further comprising an adjuvant.  
     
     
         22 . A virus-like particle that comprises the HPV-16 L1 protein of  claim 19 .  
     
     
         23 . An immunogenic composition that comprises the virus-like particle of  claim 22 .  
     
     
         24 . The immunogenic composition of  claim 23 , further comprising an adjuvant.  
     
     
         25 . An isolated HPV-16 L1 protein that lacks an N-terminal amino acid sequence encoded by nucleotides 5559 to 5636 of the HPV-16 genome.  
     
     
         26 . An immunogenic composition that comprises the HPV-16 L1 protein of  claim 25 .  
     
     
         27 . The immunogenic composition of  claim 26 , further comprising an adjuvant.  
     
     
         28 . A virus-like particle that comprises the HPV-16 L1 protein of  claim 25 .  
     
     
         29 . An immunogenic composition that comprises the virus-like particle of  claim 28 .  
     
     
         30 . The immunogenic composition of  claim 29 , further comprising an adjuvant.